Cadonilimab plus chemotherapy compared to chemotherapy as first-line treatment for persistent, recurrent, or metastatic cervical cancer in China: a cost-effectiveness analysis.

This study examined the cost-effectiveness of a treatment combination for cervical cancer in China, but does not involve acupuncture. Researchers analyzed whether adding cadonilimab (an immunotherapy drug) to standard chemotherapy was worth the additional cost compared to chemotherapy alone for women with advanced cervical cancer. The study used computer modeling based on data from the COMPASSION-16 clinical trial to estimate costs and patient outcomes over a lifetime. The results showed that while the combination treatment extended quality-adjusted life by about 0.70 years (roughly 8.5 months of good quality life), it cost an additional $50,069 per patient. The total cost per patient was $86,839 for the combination treatment versus $36,770 for chemotherapy alone. In China, where the acceptable cost threshold is $40,344 per quality-adjusted life year gained, the combination treatment was deemed not cost-effective at $71,527 per quality-adjusted life year. This economic analysis helps healthcare systems make informed decisions about which treatments to fund and make available to patients. While this study does not directly relate to acupuncture, many cancer patients use acupuncture as a complementary therapy to help manage treatment side effects like nausea, pain, and fatigue during chemotherapy. If you are considering acupuncture for cancer symptom management, consult with a licensed acupuncturist experienced in oncology supportive care.

This pharmacoeconomic analysis is not acupuncture-related but examines cadonilimab plus chemotherapy versus chemotherapy alone for metastatic cervical cancer from a Chinese healthcare perspective. Using a partitioned survival model with data from the COMPASSION-16 trial, researchers calculated lifetime costs and outcomes. The cadonilimab combination yielded an incremental gain of 0.70 quality-adjusted life years (QALYs) at an additional cost of $50,069.10 per patient (total cost $86,839.48 vs $36,770.38). The resulting incremental cost-effectiveness ratio (ICER) was $71,527.28 per QALY, exceeding China's willingness-to-pay threshold of $40,343.68. Sensitivity analyses confirmed robustness of findings. The study concluded cadonilimab plus chemotherapy is not cost-effective in China's healthcare context. This analysis has no direct implications for acupuncture practice, though acupuncture remains relevant for chemotherapy-related symptom management in cervical cancer patients.